Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

Vascular and molecular pharmacology of the metabolically stable CGRP analogue, SAX

Research output: Contribution to journalJournal articleResearchpeer-review

  1. CGRP in rat mesenteric artery and vein - receptor expression, CGRP presence and potential roles

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. The effects of CGRP in vascular tissue - Classical vasodilation, shadowed effects and systemic dilemmas

    Research output: Contribution to journalReviewResearchpeer-review

  3. Gasotransmitters and the immune system: Mode of action and novel therapeutic targets

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. Vancouver Declaration II on Global Headache Patient Advocacy 2019

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Expression of the CGRP Family of Neuropeptides and their Receptors in the Trigeminal Ganglion

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. CGRP in rat mesenteric artery and vein - receptor expression, CGRP presence and potential roles

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Cellular distribution of PACAP-38 and PACAP receptors in the rat brain: Relation to migraine activated regions

    Research output: Contribution to journalJournal articleResearchpeer-review

View graph of relations

The main purpose of this study was to compare in vitro pharmacological properties of human αCGRP (CGRP) and a recently discovered metabolically stable CGRP analogue, SAX, in isolated rat and human artery segments. In rat, CGRP and SAX induced similar vasodilatory responses in isolated mesenteric artery with the potency of SAX being lower than that of CGRP (vasodilatory pEC50 8.2 ± 0.12 and 9.0 ± 0.11, respectively). A corresponding difference in receptor binding affinity of SAX and CGRP was determined in rat cerebral membranes (pKi 8.3 ± 0.19 and 9.3 ± 0.14, respectively). CGRP and SAX-induced vasodilation was antagonised with similar potencies by the CGRP receptor antagonist BIBN4096BS supporting a uniform receptor population for the agonists. In human tissue, SAX and CGRP induced similar pharmacological responses with different potencies in subcutaneous artery (vasodilatory pEC50 8.8 ± 0.18 and 9.5 ± 0.13, respectively) and human recombinant receptors (cAMP signalling pEC50 9.1 ± 0.16 and 10.2 ± 0.19). Like in the rat mesenteric artery, both SAX and CGRP-responses were inhibited by the CGRP receptor antagonist BIBN4096BS with similar antagonistic potencies. In conclusion, all pharmacological characteristics of SAX and CGRP in human and rat sources points towards action via a uniform BIBN4096BS sensitive receptor population with the potency of SAX being 5-10 fold lower than that of CGRP.

Original languageEnglish
JournalEuropean Journal of Pharmacology
Volume829
Pages (from-to)85-92
Number of pages8
ISSN0014-2999
DOIs
Publication statusPublished - 2018

    Research areas

  • Journal Article

ID: 53670447